Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of ASP3700 in Healthy Subjects
NCT02285465Phase 1Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Nov 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing ASP3700 with Placebo (2 arms). Primary endpoints: Safety as assessed by adverse events up to 26 days, Safety as assessed by vital signs up to 26 days and 2 more. Planned start Nov 2014; status: withdrawn.
02
Drugs
ASP3700
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02285465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285465.